Please assess the completion status of the following clinical trial:

Trial Title: The SIM-SOF Trial for Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic hepatitis c,~* cirrhosis biopsy-proven, or via fibrotest,~* CPT score less than 7,~* genotype 1a,~* INR 2.3 or less,~* serum albumin greater than 2.7 gm/dL,~* total bilirubin less than 3 gm/dL,~* platelet count 50,000 per cubic milliliter or more~* GFR \>50 ml/min~Exclusion Criteria:~* non genotype 1a,~* history of CPT class B or C or decompensation or history of same,~* HIV or HBV coinfection,~* prior treatment with boceprevir, telaprevir or any other direct acting antiviral agent,~* uncontrolled psychiatric or cardiopulmonary disorders,~* planning pregnancy or unwilling/unable to practice contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard (Type: ACTIVE_COMPARATOR): Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
- Simeprevir + Sofosbuvir (Type: EXPERIMENTAL): (SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).